According to the report, treatment with PCSK9 inhibitors generates cost-effectiveness ratios that exceed the commonly-accepted $100,000 per quality-adjusted life year (QALY).

Data from a genetics-based study show PCSK9 inhibition does not affect cognition function or dementia risk; however, statin use may be associated with some impaired cognitive performance that is ...

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing ...

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...

Between PCSK9 inhibitor and the time of the analysis, median total cholesterol fell from 210 mg/dL to 133 mg/dL, median LDL fell from 125 mg/dL to 53 mg/dL, median non-HDL fell from 158 mg/dL to ...

The potential for targeting PCSK9 in people with uncontrollably high cholesterol has not yet been fully realized. When Amgen’s PCSK9 inhibitor Repatha and the rival Sanofi/Regeneron drug ...

The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across ...

Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of ...

MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...

In the last few years the PCSK9 inhibitors have been one of the few bright lights in an otherwise dismal field of new cardiovascular drugs. Now the FDA is raising questions that could dramatically ...

Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing Peer-Reviewed Publication Science China Press ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel target for low-density lipoprotein cholesterol (LDL-C)-lowering therapy, has been found to possess multiple off-target effects in ...